Gastroenterology strain | Antibiotic associated diarrhea – Prevention
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
5B/sachet or capsule
FUNCTIONALITY
AAD – Antibiotic associated diarrhea – Prevention
Scientific support
Human clinical trials
Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of High Dose Vancomycin Combined WithSaccharomyces Boulardii.”” Clinical Infectious Diseases 31.4 (2000): 1012-017.
Can, M., B. A. Besirbellioglu, I. Y. Avci, C. M. Beker, and A. Pahsa. Prophylactic Saccharomyces Boulardii in the Prevention of Antibiotic-associated Diarrhea: A Prospective Study.Medical Science Monitor 12.4 (2006): PI19-22.
Antipathogenic strain I Clostridium difficile associated diarrhea – Prevention
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
5B/sachet or capsule
FUNCTIONALITY
CDAD – Clostridium difficile associated diarrhea – Prevention
Scientific support
Human clinical trials
Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. Probiotics for the Prevention of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis.Annals of Internal Medicine 157.12 (2012): 878
Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. Is Primary Prevention of Clostridium Difficile Infection Possible with Specific Probiotics? International Journal of Infectious Diseases 6.11 (2012): E786-792.
Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of High Dose Vancomycin Combined WithSaccharomyces Boulardii.”” Clinical Infectious Diseases 31.4 (2000): 1012-017.
Mcfarland, L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. A. Moyer, S. A. Melcher, K. E. Bowen, J. L. Cox, Z. Noorani, G. Harrington, M. Rubin, and D. Greenwald. A Randomized Placebo-controlled Trial of Saccharomyces Boulardii in Combination with Standard Antibiotics for Clostridium Difficile Disease. JAMA: The Journal of the American Medical Association 271.24 (1994): 1913-918.
Antipathogenic strain I Helicobacter pylori – Adjunct to standard eradication therapy
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
5B/sachet or capsule
FUNCTIONALITY
HP – Helicobacter pylori – Adjunct to standard eradication therapy
Scientific support
Human clinical trial
Song, M. J., D.I Park, J.H. Park, H.J. Kim, Y.K. Cho, C.I. Sohn, W.K. Jeon, and B.I. Kim. The Effect of Probiotics and Mucoprotective Agents on PPI‐Based Triple Therapy for Eradication of Helicobacter pylori. Helicobacter 15.3 (2010): 206-213.
Cindoruk, M., G. Erkan,T. Karakan, A. Dursun, and S. Unal. Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study. Helicobacter 12.4 (2007): 309-316.
Szajewska, H., A. Horvath, and A. Piwowarczyk. Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Alimentary pharmacology & therapeutics 32.9 (2010): 1069-1079.
Gastroenterology strain | Ulcerative colitis – Adjunct to standard therapy
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
5B/sachet or capsule
FUNCTIONALITY
IBD-UC – IBD – Ulcerative colitis – Adjunct to standard therapy
Scientific support
Human clinical trials
Guslandi, M., G. Mezzi, M. Sorghi, and P.A. Testoni. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Digestive diseases and sciences 45.7 (2000): 1462-1464.
Guslandi, M., Giollo, P., and Testoni, P. (2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal Of Gastroenterology And Hepatology 15, 697-698.
Sivananthan, K., and Petersen, A. (2018). Review of Saccharomyces boulardii as a treatment option in IBD. Immunopharmacology And Immunotoxicology 40, 465-475.
Gastroenterology strain | Traveler’s diarrhea prevention
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
5B/sachet or capsule
FUNCTIONALITY
TD – Traveler’s diarrhea prevention
Scientific support
Human clinical trials
Kollaritsch, H., P. Kremsner, G. Wiedermann, and O. Schneider. “Prevention of traveller’s diarrhea: comparison of different non-antibiotic preparations.”” Travel Med Int 11 (1989): 9-17.
McFarland, L. V. “Meta-analysis of probiotics for the prevention of traveler’s diarrhea.” Travel medicine and infectious disease 5.2 (2007): 97-105.
